However, as results from the OCA clinical trial in PBC patients indicated, OCA was not effective against PBC-associated fibrosis21,22, suggesting that reducing BA accumulation may not be major mechanism underlying the functional benefits of FXR for liver fibrosis. Here, NR1H4 is linked to primary biliary cholangitis.